ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Debate: The First Line Treatment for Non-Complex Degenerative Mitral Valve Disease

Thursday, January 21, 2016

In a debate filmed at the 2015 SCTS Annual Meeting in Manchester, United Kingdom, Friedrich-Wilhelm Mohr and Francis Wells discuss how best to treat non-complex degenerative mitral valve disease in the 21st Century. Dr. Mohr of the Leipzig Heart Center, Leipzig, Germany, argues that minimal access surgery should be the first line in the treatment of degenerative mitral valve disease. Mr. Wells of Papworth Hospital, Cambridge, United Kingdom, argues against minimal access surgery as the first line of treatment.

These presentations were originally given during the SCTS Ionescu University program at the 80th Annual Meeting of the Society for Cardiothoracic Surgery in Great Britain and Ireland. This content is published with the permission of SCTS. Please click here for information on the 2016 SCTS Annual Meeting.

Comments

Interesting to review these learned opinions in the light of the recent New England Journal of Medicine article, indicating robustly (from a randomized trial) a mid-term non-superiority of mitral repair over replacement.

Add comment

Log in or register to post comments